Form 4: Aadi Bioscience CEO David James Lennon Acquires Stock Options and Restricted Stock Units
SEC Form 4
A Form 4 filing reveals that Aadi Bioscience CEO David James Lennon acquired stock options and restricted stock units (RSUs) on March 1, 2024, related to his compensation and continued service with the company.
Summary
- David James Lennon, CEO of Aadi Bioscience, Inc., filed a Form 4 disclosing changes in beneficial ownership.
- On March 1, 2024, Lennon acquired stock options for 30,768 shares at an exercise price of $1.92, fully vesting immediately, as part of his 2023 bonus.
- He also acquired stock options for 130,000 shares at an exercise price of $1.92, vesting over four years from March 1, 2024.
- Additionally, Lennon acquired 65,000 restricted stock units (RSUs), vesting over four years from March 1, 2024.
- The filing indicates that these acquisitions are contingent upon Lennon's continued service as a Service Provider as defined in the Issuer's 2021 Equity Incentive Plan.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the CEO's ability to drive future growth. The vesting schedules promote long-term alignment.
Positives
- The granting of stock options and RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedules encourage long-term commitment from the CEO.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and RSUs suggest an expectation of continued service from the CEO.
Industry Context
In the biotech industry, it's common to incentivize executives with stock options and RSUs to align their interests with long-term shareholder value. This is a typical compensation practice.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules are also typical, often spanning three to five years to incentivize long-term commitment.
- Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of earliest transaction, grant date for fully vested stock options, vesting commencement date for other stock options and RSUs. |
| 03/04/2024 | Date of filing the Form 4. |
| 03/01/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.